How Merck uses patents to help maintain Keytruda’s exorbitant price; International Consortium of Investigative Journalists, April 13, 2026

 Denise Ajiri and Antonio Cucho Gamboa, International Consortium of Investigative Journalists ; How Merck uses patents to help maintain Keytruda’s exorbitant price

"Merck’s original patents for Keytruda are set to expire in 2028. But Merck, using a strategy known as “evergreening,” has filed hundreds of additional patents that could protect Keytruda’s dominance well beyond that year.

ICIJ analyzed 180 U.S. patent applications related to Keytruda, provided by the Initiative for Medicines, Access & Knowledge (I-MAK), a nonprofit that examines inequities in the patent system. These were linked to 1,032 additional patent filings around the world tied to the drug. From this universe, ICIJ identified active U.S. patents that illustrate Merck’s strategy of maintaining market exclusivity.

Patents can have different status, including active, pending, abandoned, expired, or others. Explore Merck’s active U.S. Keytruda patents below."

Eli Lilly Reaches $1 Trillion in Value, Buoyed by Demand for Its Weight Loss Drugs; The New York Times, November 21, 2025

  Rebecca Robbins , The New York Times; Eli Lilly Reaches $1 Trillion in Value, Buoyed by Demand for Its Weight Loss Drugs

"Pharmaceuticals is a notoriously cyclical business. Companies buoyed by once-in-a-generation product lines flounder after their blockbuster drugs lose patent protection."

Tariffs on Medicines From Europe Stand to Cost Drugmakers Billions; The New York Times, July 28, 2025

 Rebecca Robbins, The New York Times; Tariffs on Medicines From Europe Stand to Cost Drugmakers Billions

"The trade deal reached between the United States and the European Union on Sunday will impose a 15 percent tariff on imported medicines from Europe. Drugmakers manufacture some of their biggest and best-known blockbusters there, including Botox, the cancer medication Keytruda and popular weight-loss drugs like Ozempic...

Pharmaceutical products are Europe’s No. 1 export to the United States...

Europe manufactures the active ingredients for 43 percent of the brand-name drugs consumed in the United States, according to U.S. Pharmacopeia, a nonprofit that tracks the drug supply chain. No other region produces a greater share.

Europe also makes active ingredients for 18 percent of the generic drugs taken in the United States, which have lower prices and account for a vast majority of Americans’ prescriptions."

Escaping Big Pharma’s Pricing With Patent-Free Drugs; New York Times, July 18, 2017

Fran Quigley, New York Times; Escaping Big Pharma’s Pricing With Patent-Free Drugs

"Although President Trump said before taking office that drug companies were “getting away with murder” and had campaigned on lowering drug prices, his administration is doing the opposite. A draft order on drug pricing that became public in June would grant pharmaceutical companies even more power to charge exorbitantly. For example, it could shrink a federal program that requires companies to sell at a discount to clinics and hospitals serving low-income patients.

Exorbitant prices are one thing that’s very wrong with the way we make medicines. The other is: medicines for what? If a malady has no market in wealthy countries, it gets no attention. Poor-country diseases, known as “neglected diseases,” have a ferocious impact: One of every six people in the world, including a half-billion children, suffers from neglected diseases. Yet of the 756 new drugs approved between 2001 and 2011, less than 4 percent targeted those diseases. The industry spends far more on lobbying government agencies to extend monopolies on high-cost drugs — or hand out deals like the Zika vaccine — than it does on research for a vaccine against dengue fever, which poses a risk for 40 percent of the world’s population.

But there’s one drug company that behaves differently."